Guindalini, Rodrigo Santa Cruz
Viana, Danilo Vilela
Kitajima, João Paulo Fumio Whitaker
Rocha, Vinícius Marques
López, Rossana Verónica Mendoza
Zheng, Yonglan
Freitas, Érika
Monteiro, Fabiola Paoli Mendes
Valim, André
Schlesinger, David
Kok, Fernando
Olopade, Olufunmilayo I.
Folgueira, Maria Aparecida Azevedo Koike
Article History
Received: 26 July 2021
Accepted: 1 February 2022
First Online: 9 March 2022
Competing interests
: Founders and employees of Mendelics Análise Genômica served as coinvestigators in this study and provided material support, including germline testing and interpretation, as described in the manuscript. The specific coinvestigators listed as authors participated in the review and final approval of the submitted manuscript. R.S.C.G. acted as a consultant for AstraZeneca, GlaxoSmithKline and Igenomix; received speaker honoraria from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Merck Sharpe & Dohme Brasil, Novartis, and Roche outside the submitted work; and has equity in Mendelics Análise Genômica. J.P.F.W.K., A.V., D.S. and F.K. are co-founders at Mendelics Análise Genômica. O.I.O. is co-founder at CancerIQ; serves as scientific advisor at Tempus; and is on the advisory board of 54gene. All the other authors declare no competing interests.